核ErbB-2: ErbB-2阳性乳腺癌的新治疗靶点?

IF 3 4区 医学 Q3 Biochemistry, Genetics and Molecular Biology
Rosalía I Cordo Russo, María F Chervo, Santiago Madera, Eduardo H Charreau, Patricia V Elizalde
{"title":"核ErbB-2: ErbB-2阳性乳腺癌的新治疗靶点?","authors":"Rosalía I Cordo Russo,&nbsp;María F Chervo,&nbsp;Santiago Madera,&nbsp;Eduardo H Charreau,&nbsp;Patricia V Elizalde","doi":"10.1007/s12672-018-0356-3","DOIUrl":null,"url":null,"abstract":"<p><p>Membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbB family of receptor tyrosine kinases, occurs in 15-20% of breast cancers (BC) and constitutes a therapeutic target in this BC subtype (ErbB-2-positive). Although MErbB-2-targeted therapies have significantly improved patients' clinical outcome, resistance to available drugs is still a major issue in the clinic. Lack of accurate biomarkers for predicting responses to anti-ErbB-2 drugs at the time of diagnosis is also an important unresolved issue. Hence, a better understanding of the ErbB-2 signaling pathway constitutes a critical task in the battle against BC. In its canonical mechanism of action, MErbB-2 activates downstream signaling pathways, which transduce its proliferative effects in BC. The dogma of ErbB-2 mechanism of action has been challenged by the demonstration that MErbB-2 migrates to the nucleus, where it acts as a transcriptional regulator. Accumulating findings demonstrate that nuclear ErbB-2 (NErbB-2) is involved in BC growth and metastasis. Emerging evidence also reveal a role of NErbB-2 in the response to available anti-MErbB-2 agents. Here, we will review NErbB-2 function in BC and will particularly discuss the role of NErbB-2 as a novel target for therapy in ErbB-2-positive BC.</p>","PeriodicalId":13060,"journal":{"name":"Hormones & Cancer","volume":"10 2-3","pages":"64-70"},"PeriodicalIF":3.0000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12672-018-0356-3","citationCount":"9","resultStr":"{\"title\":\"Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?\",\"authors\":\"Rosalía I Cordo Russo,&nbsp;María F Chervo,&nbsp;Santiago Madera,&nbsp;Eduardo H Charreau,&nbsp;Patricia V Elizalde\",\"doi\":\"10.1007/s12672-018-0356-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbB family of receptor tyrosine kinases, occurs in 15-20% of breast cancers (BC) and constitutes a therapeutic target in this BC subtype (ErbB-2-positive). Although MErbB-2-targeted therapies have significantly improved patients' clinical outcome, resistance to available drugs is still a major issue in the clinic. Lack of accurate biomarkers for predicting responses to anti-ErbB-2 drugs at the time of diagnosis is also an important unresolved issue. Hence, a better understanding of the ErbB-2 signaling pathway constitutes a critical task in the battle against BC. In its canonical mechanism of action, MErbB-2 activates downstream signaling pathways, which transduce its proliferative effects in BC. The dogma of ErbB-2 mechanism of action has been challenged by the demonstration that MErbB-2 migrates to the nucleus, where it acts as a transcriptional regulator. Accumulating findings demonstrate that nuclear ErbB-2 (NErbB-2) is involved in BC growth and metastasis. Emerging evidence also reveal a role of NErbB-2 in the response to available anti-MErbB-2 agents. Here, we will review NErbB-2 function in BC and will particularly discuss the role of NErbB-2 as a novel target for therapy in ErbB-2-positive BC.</p>\",\"PeriodicalId\":13060,\"journal\":{\"name\":\"Hormones & Cancer\",\"volume\":\"10 2-3\",\"pages\":\"64-70\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2019-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s12672-018-0356-3\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hormones & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12672-018-0356-3\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormones & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-018-0356-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 9

摘要

ErbB-2 (MErbB-2)是ErbB受体酪氨酸激酶家族的一员,其膜过表达发生在15-20%的乳腺癌(BC)中,并构成该BC亚型(ErbB-2阳性)的治疗靶点。尽管merbb -2靶向治疗已经显著改善了患者的临床结果,但对现有药物的耐药性仍然是临床中的一个主要问题。在诊断时缺乏准确的生物标志物来预测抗erbb -2药物的反应也是一个重要的未解决的问题。因此,更好地了解ErbB-2信号通路是对抗BC的关键任务。在其典型的作用机制中,MErbB-2激活下游信号通路,从而传导其在BC中的增殖作用。MErbB-2迁移到细胞核作为转录调节因子的研究,对ErbB-2作用机制的教条提出了挑战。越来越多的研究结果表明,核ErbB-2 (NErbB-2)参与了BC的生长和转移。新出现的证据也揭示了NErbB-2在对可用的抗merbb -2药物的反应中的作用。在这里,我们将回顾NErbB-2在BC中的功能,并将特别讨论NErbB-2作为erbb -2阳性BC治疗的新靶点的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?

Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?

Membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbB family of receptor tyrosine kinases, occurs in 15-20% of breast cancers (BC) and constitutes a therapeutic target in this BC subtype (ErbB-2-positive). Although MErbB-2-targeted therapies have significantly improved patients' clinical outcome, resistance to available drugs is still a major issue in the clinic. Lack of accurate biomarkers for predicting responses to anti-ErbB-2 drugs at the time of diagnosis is also an important unresolved issue. Hence, a better understanding of the ErbB-2 signaling pathway constitutes a critical task in the battle against BC. In its canonical mechanism of action, MErbB-2 activates downstream signaling pathways, which transduce its proliferative effects in BC. The dogma of ErbB-2 mechanism of action has been challenged by the demonstration that MErbB-2 migrates to the nucleus, where it acts as a transcriptional regulator. Accumulating findings demonstrate that nuclear ErbB-2 (NErbB-2) is involved in BC growth and metastasis. Emerging evidence also reveal a role of NErbB-2 in the response to available anti-MErbB-2 agents. Here, we will review NErbB-2 function in BC and will particularly discuss the role of NErbB-2 as a novel target for therapy in ErbB-2-positive BC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hormones & Cancer
Hormones & Cancer ONCOLOGY-ENDOCRINOLOGY & METABOLISM
CiteScore
4.60
自引率
0.00%
发文量
0
期刊介绍: Hormones and Cancer is a unique multidisciplinary translational journal featuring basic science, pre-clinical, epidemiological, and clinical research papers. It covers all aspects of the interface of Endocrinology and Oncology. Thus, the journal covers two main areas of research: Endocrine tumors (benign & malignant tumors of hormone secreting endocrine organs) and the effects of hormones on any type of tumor. We welcome all types of studies related to these fields, but our particular attention is on translational aspects of research. In addition to basic, pre-clinical, and epidemiological studies, we encourage submission of clinical studies including those that comprise small series of tumors in rare endocrine neoplasias and/or negative or confirmatory results provided that they significantly enhance our understanding of endocrine aspects of oncology. The journal does not publish case studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信